These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33505033)

  • 1. How ecstasy and psilocybin are shaking up psychiatry.
    Tullis P
    Nature; 2021 Jan; 589(7843):506-509. PubMed ID: 33505033
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychedelic drugs: the ups and downs of ecstasy.
    Check E
    Nature; 2004 May; 429(6988):126-8. PubMed ID: 15141183
    [No Abstract]   [Full Text] [Related]  

  • 3. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
    Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
    J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin and MDMA for the treatment of trauma-related psychopathology.
    Bird CIV; Modlin NL; Rucker JJH
    Int Rev Psychiatry; 2021 May; 33(3):229-249. PubMed ID: 34121583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not imagining it. Research into hallucinogens cautiously resumes.
    Biello D
    Sci Am; 2006 Nov; 295(5):33-5. PubMed ID: 17076078
    [No Abstract]   [Full Text] [Related]  

  • 10. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
    Haridy R
    Nature; 2023 Jul; 619(7969):227-228. PubMed ID: 37386185
    [No Abstract]   [Full Text] [Related]  

  • 12. Can psychedelics have a role in psychiatry once again?
    Sessa B
    Br J Psychiatry; 2005 Jun; 186():457-8. PubMed ID: 15928353
    [No Abstract]   [Full Text] [Related]  

  • 13. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
    Nogrady B
    BMJ; 2023 Jul; 382():1599. PubMed ID: 37433614
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promises and perils of psychedelic pharmacology for psychiatry.
    McClure-Begley TD; Roth BL
    Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
    Abramson HA; Rolo A
    J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
    Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
    Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
    Mithoefer MC; Grob CS; Brewerton TD
    Lancet Psychiatry; 2016 May; 3(5):481-8. PubMed ID: 27067625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.